

# Recessive Dystrophic Epidermolysis (RDEB)- Pipeline Insight, 2019

<https://marketpublishers.com/r/RDFD188443AEN.html>

Date: August 2019

Pages: 60

Price: US\$ 1,250.00 (Single User License)

ID: RDFD188443AEN

## Abstracts

This report can be delivered to the clients within 24 Hours

"Recessive Dystrophic Epidermolysis (RDEB)- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Recessive Dystrophic Epidermolysis pipeline landscape is provided which includes the disease overview and Recessive Dystrophic Epidermolysis treatment guidelines. The assessment part of the report embraces, in depth Recessive Dystrophic Epidermolysis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recessive Dystrophic Epidermolysis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

### Recessive Dystrophic Epidermolysis Understanding

Recessive dystrophic epidermolysis bullosa is an inherited blistering skin disorder caused by mutations in the COL7A1 gene-encoding type VII collagen (Col7), the major component of anchoring fibrils at the dermal–epidermal junction. Individuals with RDEB develop painful blisters and mucosal erosions. RDEB can be further classified as Severe Generalised and Generalised Intermediate. Severe Generalized - In this form, the skin is extremely fragile, often with extensive blistering and wounds. There is usually no collagen VII present. Wounds tend to heal with a scar that can lead to contractures and impaired movement, particularly affecting the hands. Generalised Intermediate– In this form, there is usually some collagen VII present in the skin. There is a tendency for the skin to blister and for wounds to develop, the extent being dependent on the amount

of collagen VII present. The lining of the mouth and esophagus are usually fragile. The hands will be scarred with some contractures but the severity is less than those with RDEB-SG.

### Recessive Dystrophic Epidermolysis Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Recessive Dystrophic Epidermolysis targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Recessive Dystrophic Epidermolysis pipeline report covers 10+ companies. Some of the key players include Fibrocell Science (FCX 007), Abeona Therapeutics (EB 101) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

### Recessive Dystrophic Epidermolysis Analytical Perspective by DelveInsight

#### In-depth Recessive Dystrophic Epidermolysis Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

#### Recessive Dystrophic Epidermolysis Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

## Scope of the report

The Recessive Dystrophic Epidermolysis report provides an overview of therapeutic pipeline activity for Recessive Dystrophic Epidermolysis across the complete product development cycle including all clinical and non-clinical stages

It comprises of detailed profiles of Recessive Dystrophic Epidermolysis therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details

Detailed Recessive Dystrophic Epidermolysis Research and Development progress and trial details, results wherever available, are also included in the pipeline study

Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type

Coverage of dormant and discontinued pipeline projects along with the reasons if available across Recessive Dystrophic Epidermolysis

## Reasons to Buy

Establish a comprehensive understanding of the current pipeline scenario across Recessive Dystrophic Epidermolysis to formulate effective R&D strategies

Assess challenges and opportunities that influence Recessive Dystrophic Epidermolysis R&D

Develop strategic initiatives by understanding the focus areas of leading companies.

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Get in detail information of each product with updated information on each

project along with key milestones

Devise Recessive Dystrophic Epidermolysis in licensing and out licensing strategies by identifying prospective partners with progressing projects for Recessive Dystrophic Epidermolysis to enhance and expand business potential and scope

Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs

## Contents

### 1. REPORT INTRODUCTION

### 2. RECESSIVE DYSTROPHIC EPIDERMOLYSIS

- 2.1. Recessive Dystrophic Epidermolysis Disease Overview
- 2.2. Recessive Dystrophic Epidermolysis History
- 2.3. Recessive Dystrophic Epidermolysis Symptoms
- 2.4. Recessive Dystrophic Epidermolysis Causes
- 2.5. Recessive Dystrophic Epidermolysis Pathophysiology
- 2.6. Recessive Dystrophic Epidermolysis Diagnosis
  - 2.6.1. Diagnostic Guidelines

### 3. RECESSIVE DYSTROPHIC EPIDERMOLYSIS CURRENT TREATMENT PATTERNS

- 3.1. Treatment Guidelines

### 4. RECESSIVE DYSTROPHIC EPIDERMOLYSIS- DELVEINSIGHT'S ANALYTICAL PERSPECTIVE

- 4.1. In-depth Commercial Assessment
  - 4.1.1. Recessive Dystrophic Epidermolysis companies collaborations, Licensing, Acquisition –Deal Value Trends
    - 4.1.1.1. Assessment Summary
  - 4.1.2. Recessive Dystrophic Epidermolysis Collaboration Deals
    - 4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    - 4.1.2.2. Recessive Dystrophic Epidermolysis Acquisition Analysis
- 4.2. Clinical Assessment of Pipeline Drugs
  - 4.2.1. Assessment by Phase of Development
  - 4.2.2. Assessment by Product Type (Mono / Combination)
    - 4.2.2.1. Assessment by Stage and Product Type
  - 4.2.3. Assessment by Route of Administration
    - 4.2.3.1. Assessment by Stage and Route of Administration
  - 4.2.4. Assessment by Molecule Type
    - 4.2.4.1. Assessment by Stage and Molecule Type
  - 4.2.5. Assessment by MOA
    - 4.2.5.1. Assessment by Stage and MOA

## **5. RECESSIVE DYSTROPHIC EPIDERMOLYSIS PIPELINE THERAPEUTICS**

- 5.1. Late Stage Products (Phase-III)
  - 5.1.1. Comparative Analysis
- 5.2. Mid Stage Products (Phase-II)
  - 5.2.1. Comparative Analysis
- 5.3. Early Stage Products (Phase-I)
  - 5.3.1. Comparative Analysis
- 5.4. Pre-clinical and Discovery Stage Products
  - 5.4.1. Comparative Analysis
- 5.5. Inactive Products

## **6. RECESSIVE DYSTROPHIC EPIDERMOLYSIS-PRODUCTS ANALYSIS**

- 6.1. Product Profiles
  - 6.1.1. FCX 007- Fibrocell Science
    - 6.1.1.1. Product Description
      - 6.1.1.1.1. Product Overview
      - 6.1.1.1.2. Mechanism of Action
    - 6.1.1.2. Research and Development
      - 6.1.1.2.1. Clinical Studies
        - 6.1.1.2.1.1. Detailed Study Description
        - 6.1.1.2.1.2. Study Results
        - 6.1.1.2.1.3. Clinical Trials: Tabular View
      - 6.1.1.3. Product Development Activities
        - 6.1.1.3.1. Tabulated Product Summary
          - 6.1.1.3.1.1. General Description Table
  - 6.1.2. EB 101- Abeona Therapeutics
    - 6.1.2.1. Product Description
      - 6.1.2.1.1. Product Overview
      - 6.1.2.1.2. Mechanism of Action
    - 6.1.2.2. Research and Development
      - 6.1.2.2.1. Clinical Studies
        - 6.1.2.2.1.1. Detailed Study Description
        - 6.1.2.2.1.2. Study Results
        - 6.1.2.2.1.3. Clinical Trials: Tabular View
      - 6.1.2.3. Product Development Activities
        - 6.1.2.3.1. Tabulated Product Summary

#### 6.1.2.3.1.1. General Description Table

To be continued in the report.....

## **7. RECENT TECHNOLOGIES**

## **8. RECESSIVE DYSTROPHIC EPIDERMOLYSIS KEY COMPANIES**

- 8.1. Fibrocell Science
- 8.2. Abeona Therapeutics
- 8.3. Immusoft
- 8.4. Intercytex
- 8.5. Takeda
- 8.6. ProQR Therapeutics
- 8.7. Amicus Therapeutics
- 8.8. Krystal Biotech
- 8.9. Constant Therapeutics
- 8.10. Celgene Corporation

## **9. RECESSIVE DYSTROPHIC EPIDERMOLYSIS KEY PRODUCTS**

- 9.1. FCX 007
- 9.2. EB 101
- 9.3. Research programme: recessive dystrophic epidermyolysis bullosa therapy
- 9.4. ICX RHY
- 9.5. PTR 01
- 9.6. QR 313
- 9.7. Allantoin
- 9.8. Bercolagene telsepavec
- 9.9. Angiotensin-1-7
- 9.10. PSC 100

## **10. DORMANT AND DISCONTINUED PRODUCTS**

- 10.1. Dormant Products
  - 10.1.1. Reasons for being dormant
- 10.2. Discontinued Products
  - 10.2.1. Reasons for the discontinuation

## **11. RECESSIVE DYSTROPHIC EPIDERMOLYSIS- UNMET NEEDS**

## **12. RECESSIVE DYSTROPHIC EPIDERMOLYSIS- FUTURE PERSPECTIVES**

## **13. APPENDIX**

## **14. REPORT METHODOLOGY**

14.1. Secondary Research

14.2. Expert Panel Validation



## List Of Tables

### LIST OF TABLES

- Table 1. Recessive Dystrophic Epidermolysis Diagnostic Guidelines
- Table 2. Treatment Guidelines
- Table 3. Assessment Summary
- Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
- Table 5. Recessive Dystrophic Epidermolysis Acquisition Analysis
- Table 6. Assessment by Phase of Development
- Table 7. Assessment by Product Type (Mono / Combination)
- Table 8. Assessment by Stage and Product Type
- Table 9. Assessment by Route of Administration
- Table 10. Assessment by Stage and Route of Administration
- Table 11. Assessment by Molecule Type
- Table 12. Assessment by Stage and Molecule Type
- Table 13. Assessment by MOA
- Table 14. Assessment by Stage and MOA
- Table 15. Late Stage Products (Phase-III)
- Table 16. Mid Stage Products (Phase-II)
- Table 17. Early Stage Products (Phase-I)
- Table 18. Pre-clinical and Discovery Stage Products
- Table 19. Inactive Products
- Table 20. Dormant Products
- Table 21. Discontinued Products

## List Of Figures

### LIST OF FIGURES

- Figure 1. Disease Overview
- Figure 2. History
- Figure 3. Symptoms
- Figure 4. Causes
- Figure 5. Pathophysiology
- Figure 6. Diagnostic Guidelines
- Figure 7. Treatment Guidelines
- Figure 8. Recessive Dystrophic Epidermolysis companies collaborations, Licensing, Acquisition –Deal Value Trends
- Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
- Figure 10. Recessive Dystrophic Epidermolysis Acquisition Analysis
- Figure 11. Assessment by Phase of Development
- Figure 12. Assessment by Product Type (Mono / Combination)
- Figure 13. Assessment by Stage and Product Type
- Figure 14. Assessment by Route of Administration
- Figure 15. Assessment by Stage and Route of Administration
- Figure 16. Assessment by Molecule Type
- Figure 17. Assessment by Stage and Molecule Type
- Figure 18. Assessment by MOA
- Figure 19. Assessment by Stage and MOA
- Figure 20. Late Stage Products (Phase-III)
- Figure 21. Mid Stage Products (Phase-II)
- Figure 22. Early Stage Products (Phase-I)
- Figure 23. Pre-clinical and Discovery Stage Products
- Figure 24. Inactive Products
- Figure 25. Dormant Products
- Figure 26. Discontinued Products
- Figure 27. Unmet Needs

### KEY COMPANIES

Fibrocell Science  
Abeona Therapeutics  
Immusoft  
Intercytex

Takeda  
ProQR Therapeutics  
Amicus Therapeutics  
Krystal Biotech  
Constant Therapeutics  
Celularity

## I would like to order

Product name: Recessive Dystrophic Epidermolysis (RDEB)- Pipeline Insight, 2019

Product link: <https://marketpublishers.com/r/RDFD188443AEN.html>

Price: US\$ 1,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RDFD188443AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970